NTRB Overview

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Wall Street analysts forecast NTRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRB is15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Nutriband Inc revenue for the last quarter amounts to 346.06K USD, decreased -46.41

Nutriband Inc. EPS for the last quarter amounts to -0.32 USD, increased 166.67

Nutriband Inc (NTRB) has 3 emplpoyees as of March 17 2026.

Today NTRB has the market capitalization of 46.26M USD.